vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"vestim-281Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEКлинико-морфологический анализ отечно-инфильтративной формы рака молочной железыClinical and morphological analysis of inflammatory breast cancerТретьякИ. Ю.TratsiakI. Y.irinatratsiak@gmail.comДемидчикЮ. Е.DemidchikY. E.noemail@neicon.ruКостюкС. А.KostiukS. A.noemail@neicon.ruБелорусская медицинская академия последипломного образованияБеларусьBelarusian Medical Academy of Postgraduate EducationBelarus20160101201601410Copyright © Третьяк И.Ю., Демидчик Ю.Е., Костюк С.А., 20162016Третьяк И.Ю., Демидчик Ю.Е., Костюк С.А.Tratsiak I.Y., Demidchik Y.E., Kostiuk S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/281

В ходе исследования проанализирована первичная медицинская документация 192 пациенток с установленным в 2009-2013 гг. диагнозом «рак молочной железы cT4N0-3M0». Выявлены статистически значимые различия в общей выживаемости и выживаемости без прогрессирования заболевания в зависимости от вовлеченности регионарных лимфатических узлов (cN0-2 против cN3), а также в зависимости от применения или неприменения хирургического лечения и дистанционной лучевой терапии (p < 0,05). Определены статистически значимые различия в беспрогрессивной (p = 0,022), но не в общей выживаемости (p = 0,971) в зависимости использования или неиспользования нео-адъювантной химиотерапии (НПХТ). На достижение объективного ответа на НПХТ с включением антрациклинов оказывали влияние гормон-рецепторный статус, молекулярно-генетический подтип (p < 0,05), но не гистологические характеристики опухоли (p > 0,05).

We analyzed the primary medical documentation of 192 patients with the established in 2009-2013 diagnosis "breast cancer stage cT4N0-3M0". There were statistically significant differences in overall and progression-free survival depending on both the degree of involved regional lymph nodes (cN0-2 vs cN3) and the use of surgery and radiotherapy (p < 0.05). Statistically significant differences in progression-free (p = 0.022), but not in overall survival (p = 0.971) according to use/no use of neoadjuvant chemotherapy were identified. The objective response to neoadjuvant chemotherapy with the inclusion of anthracycline was influenced by the hormone-receptor status, as well as by the molecular genetic subtype (p < 0.05), but not by the histologic characteristics of the tumor (p > 0.05).

ReferencesTNM classification of malignant tumors / L. Sobin [et al.]. - New York, 2002. - P. 336.TNM classification of malignant tumors / L. Sobin [et al.]. - New York, 2002. - P. 336.Портной, С. М. Лечение местнораспространенного рака молочной железы / С. М. Портной // Сибир. онкол. журн. - 2008. - Прил. № 2. - С. 14-22.Портной, С. М. Лечение местнораспространенного рака молочной железы / С. М. Портной // Сибир. онкол. журн. - 2008. - Прил. № 2. - С. 14-22.Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) Program / P. H. Levine [et al.] // J. Natl. Cancer Inst. - 1985. - Vol. 74. - P. 291-297.Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) Program / P. H. Levine [et al.] // J. Natl. Cancer Inst. - 1985. - Vol. 74. - P. 291-297.Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992 / S. Chang [et al.] // Cancer. - 1998. - Vol. 82. - P. 2366-2372.Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992 / S. Chang [et al.] // Cancer. - 1998. - Vol. 82. - P. 2366-2372.Jaiyesimi, I. A. Inflammatory breast cancer: a review / I. A. Jaiyesimi, A. U. Buzdar, G. Hortobagyi // J. Clin. Oncol. -1992. - Vol. 10. - P. 1014-1024.Jaiyesimi, I. A. Inflammatory breast cancer: a review / I. A. Jaiyesimi, A. U. Buzdar, G. Hortobagyi // J. Clin. Oncol. -1992. - Vol. 10. - P. 1014-1024.Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy / J. Rouesse [et al.] // J. Clin. Oncol. - 1986. - Vol. 4. - P. 1765-1771.Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy / J. Rouesse [et al.] // J. Clin. Oncol. - 1986. - Vol. 4. - P. 1765-1771.Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience / A. U. Buzdar [et al.] // Surg. Oncol. Clin. - 1995. - Vol. 4. - P. 715-734.Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience / A. U. Buzdar [et al.] // Surg. Oncol. Clin. - 1995. - Vol. 4. - P. 715-734.Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results program at the National Cancer Institute / K. W. Hance [et al.] // J. Natl. Cancer Inst. - 2005. - Vol. 97. - P. 966-975.Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results program at the National Cancer Institute / K. W. Hance [et al.] // J. Natl. Cancer Inst. - 2005. - Vol. 97. - P. 966-975.Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy / J. A. Low [et al.] // J. Clin. Oncol. - 2004. - Vol. 22. - P. 4067-4074.Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy / J. A. Low [et al.] // J. Clin. Oncol. - 2004. - Vol. 22. - P. 4067-4074.Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast / J. C. Delarue [et al.] // Br. J. Cancer. - 1981. - Vol. 44. - P. 911-991.Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast / J. C. Delarue [et al.] // Br. J. Cancer. - 1981. - Vol. 44. - P. 911-991.Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease / A. Paradiso [et al.] // Cancer. - 1989. - Vol. 64. - P. 1922-1927.Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease / A. Paradiso [et al.] // Cancer. - 1989. - Vol. 64. - P. 1922-1927.Lerebours, F. Update on inflammatory breast cancer / F. Lerebours, I. Bieche, R. Lidereau // Breast Cancer Res. -2005. - Vol. 7, N 2. - P. 52-58.Lerebours, F. Update on inflammatory breast cancer / F. Lerebours, I. Bieche, R. Lidereau // Breast Cancer Res. -2005. - Vol. 7, N 2. - P. 52-58.Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience / S. A. Aziz [et al.] // Breast J. - 2001. - Vol. 7. - P. 398-404.Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience / S. A. Aziz [et al.] // Breast J. - 2001. - Vol. 7. - P. 398-404.Giordano, S. H. Inflammatory breast cancer: clinical progress and the main problems that must be addressed / S. H. Giordano, G. N. Hortobagyi // Breast Cancer Res. - 2003. - Vol. 5, N 6. - P. 284-288.Giordano, S. H. Inflammatory breast cancer: clinical progress and the main problems that must be addressed / S. H. Giordano, G. N. Hortobagyi // Breast Cancer Res. - 2003. - Vol. 5, N 6. - P. 284-288.Multimodality therapy in inflammatory breast cancer: is there a place for surgery? / R. H. De Boer [et al.] // Ann. Oncol. - 2000. - Vol. 11, N 9. - P. 1147-1153.Multimodality therapy in inflammatory breast cancer: is there a place for surgery? / R. H. De Boer [et al.] // Ann. Oncol. - 2000. - Vol. 11, N 9. - P. 1147-1153.Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma / R. Y. Fleming [et al.] // Ann. Surg. Oncol. - 1997. - Vol. 4. - P. 452-461.Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma / R. Y. Fleming [et al.] // Ann. Surg. Oncol. - 1997. - Vol. 4. - P. 452-461.Hagelberg, R. S. Role of surgery in the treatment of inflammatory breast carcinoma / R. S. Hagelberg, P. C. Jolly, R. P. Anderson // Am. J. Surg. - 1984. - Vol. 148. - P. 125-131.Hagelberg, R. S. Role of surgery in the treatment of inflammatory breast carcinoma / R. S. Hagelberg, P. C. Jolly, R. P. Anderson // Am. J. Surg. - 1984. - Vol. 148. - P. 125-131.Ten-year outcome after combined modality therapy for inflammatory breast cancer / E. E. R. Harris [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2003. - Vol. 55. - P. 1200-1208.Ten-year outcome after combined modality therapy for inflammatory breast cancer / E. E. R. Harris [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2003. - Vol. 55. - P. 1200-1208.Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma / C. A. Perez [et al.] // Cancer. - 1994. - Vol. 74. - P. 466-476.Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma / C. A. Perez [et al.] // Cancer. - 1994. - Vol. 74. - P. 466-476.Sinclair, S. Primary systemic chemotherapy for inflammatory breast cancer / S. Sinclair, S. M. Swain // Cancer. -2010. - Vol. 116, N 11. - P. 2821-2828.Sinclair, S. Primary systemic chemotherapy for inflammatory breast cancer / S. Sinclair, S. M. Swain // Cancer. -2010. - Vol. 116, N 11. - P. 2821-2828.Kell, M. R. Surgical aspects of inflammatory breast cancer / M. R. Kell, M. Morrow // Breast Dis. - 2005. - Vol. 22. - P. 67-73.Kell, M. R. Surgical aspects of inflammatory breast cancer / M. R. Kell, M. Morrow // Breast Dis. - 2005. - Vol. 22. - P. 67-73.Inflammatory breast cancer: the disease, the biology, the treatment / F. M. Robertson [et al.] // CA Cancer J. Clin. -2010. - Vol. 60, N 6. - P. 351-375.Inflammatory breast cancer: the disease, the biology, the treatment / F. M. Robertson [et al.] // CA Cancer J. Clin. -2010. - Vol. 60, N 6. - P. 351-375.NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Updates. 2013. Version 2 NCCN guidelines. Available at: http://www.nccn.org/. 2009.NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Updates. 2013. Version 2 NCCN guidelines. Available at: http://www.nccn.org/. 2009.Long-term results of combined-modality therapy for inflammatory breast carcinoma / E. Baldini [et al.] // Clin. Breast Cancer. - 2004. - Vol. 5, N 5. - P. 358-363.Long-term results of combined-modality therapy for inflammatory breast carcinoma / E. Baldini [et al.] // Clin. Breast Cancer. - 2004. - Vol. 5, N 5. - P. 358-363.High incidence of HER-2 positivity in inflammatory breast cancer / M. Parton [et al.] // Breast. - 2004. - Vol. 13, N 2. - P. 97-103.High incidence of HER-2 positivity in inflammatory breast cancer / M. Parton [et al.] // Breast. - 2004. - Vol. 13, N 2. - P. 97-103.High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer / M. Sawaki [et al.] // Breast Cancer. - 2006. - Vol. 13, N 2. - P. 172-178.High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer / M. Sawaki [et al.] // Breast Cancer. - 2006. - Vol. 13, N 2. - P. 172-178.Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer / E. Turpin [et al.] // Oncogene. - 2002. - Vol. 21, N 49. - P. 7593-7597.Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer / E. Turpin [et al.] // Oncogene. - 2002. - Vol. 21, N 49. - P. 7593-7597.Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 / D. J. Slamon [et al.] // Science. - 1987. - Vol. 235. - P. 177-182.Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 / D. J. Slamon [et al.] // Science. - 1987. - Vol. 235. - P. 177-182.Полиморфизм генов глутатион^-трансфераз и результаты химиотерапии рака яичников / А. А. Моисеев [и др.] // Вестн. рос. онкол. науч. центра имени Н. Н. Блохина РАМН. - 2008. - Т. 19, № 1. - С. 59-64.Полиморфизм генов глутатион^-трансфераз и результаты химиотерапии рака яичников / А. А. Моисеев [и др.] // Вестн. рос. онкол. науч. центра имени Н. Н. Блохина РАМН. - 2008. - Т. 19, № 1. - С. 59-64.Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy / R. L. Bauer [et al.] // Ann. Surg. Oncol. - 1995. - Vol. 2, N 4. - P. 288-294.Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy / R. L. Bauer [et al.] // Ann. Surg. Oncol. - 1995. - Vol. 2, N 4. - P. 288-294.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1,1) / E. A. Eisenhauer [et al.] // Eur. J. of Cancer. - 2009. - Vol. 45. - P. 228-247.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1,1) / E. A. Eisenhauer [et al.] // Eur. J. of Cancer. - 2009. - Vol. 45. - P. 228-247.

The authors declare that there are no conflicts of interest present.